This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Extrapyramidal Side Effects, Tardive Dyskinesia, and the Concept of Atypicality

William M. Glazer, MD

Published: March 31, 2000

Article Abstract

The most frequent problems associated with the older generation of antipsychotic agents are extrapyramidalside effects (EPS) and tardive dyskinesia. Neuroleptic-induced EPS are thought to becaused by blockade of nigrostriatal dopamine tracts resulting in a relative increase in cholinergic activity;tardive dyskinesia is less well understood but is thought to be a supersensitivity response tochronic dopamine blockade. The leading hypothesis for the mechanism of action of the newer generationof atypical antipsychotics is the presence of a high serotonin-to-dopamine receptor blockade ratioin the brain. When serotonergic activity is blocked—as is the case with atypical antipsychotics—dopamine release increases and balances out the dopamine blockade effect at postsynaptic receptorsites, which results in few or no EPS. Prospective data indicate that the risk of tardive dyskinesia inpatients taking atypical antipsychotics is less than that for those taking typical antipsychotics. Thisarticle reviews the mechanisms of neuroleptic-induced EPS and tardive dyskinesia and discusses therelationship between these movement disorders and atypical antipsychotic agents.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...